CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas

SOON A. PARK1, CHUNG HEON RYU1, SEONG MUK KIM1, JUNG YEON LIM1, SANG IN PARK1, CHANG HYUN JEONG1, JIN AE JUN1, JI HYEON OH1, SUN HWA PARK1, WONIL OH3 and SIN-SOO JEUN1,2

Departments of 1Biomedical Science, College of Medicine, and 2Neurosurgery, Seoul St. Mary’s Hospital, The Catholic University of Korea; 3Medipost Biomedical Research Institute, Medipost Co., Ltd., Seoul, Republic of Korea

Received July 30, 2010; Accepted September 2, 2010

DOI: 10.3892/ijo_00000828

Abstract. Mesenchymal stem cells (MSCs) can be used as a delivery vehicle for gene therapy against brain tumors, because these cells have a migratory capacity toward glioma cells. Soluble factors including chemokines or growth factors expressed and released by glioma cells mediate the tropism of MSCs for gliomas. Among them, stromal cell-derived factor-1α (SDF-1α) has been identified as a key molecule related to the tropism of MSC in many cancers containing gliomas. In this study, we found that overexpression of the SDF-1α receptor, CXCR4, on human umbilical cord blood-derived MSCs (hUCB-MSCs) enhanced the migratory capacity of MSCs toward gliomas. We showed that hUCB-MSCs have the migration ability toward the glioma cell lines and primary glioma cells. SDF-1α treatment increased the migration capacity of hUCB-MSCs in a dose-dependent manner and inhibition of SDF-1α or CXCR4 by treatment with the anti-SDF-1α or the CXCR4 antagonist AMD3100 blocked the migration capacity of hUCB-MSCs toward glioma cells. Furthermore, CXCR4-overexpressed hUCB-MSCs (hMSCs-CXCR4) showed a stronger migration capacity toward glioma cells in vitro compared with control MSCs, and also exhibited enhanced migration to glioma cells in an intracranial human malignant glioma xenograft model. These results indicate that SDF-1α/CXCR4 could be involved in recruitment of hUCB-MSCs to glioma cells and that overexpression of CXCR4 may be a useful tool for stem cell-based glioma therapy.

Introduction

Malignant gliomas are a type of tumor that arises from glial cells in the brain. The prognosis of patients with median survival is still 1 year because gliomas are refractory to conventional treatments, such as extensive surgical resection, radiation, chemotherapy and gene therapy (1,2). This treatment resistance is partly due to the infiltration and invasion of gliomas into surrounding brain architecture. Recent new therapies for brain tumors have prompted the proposal, that neural stem cells (NSCs) with tumor tropism may be used as a vehicle for the delivery of therapeutic agents to target the tumor (3-5).

However, the clinical application of NSCs is limited by ethical and logistic problems related to their isolation and immunologic incompatibility in allogenic transplantation (6,7). Ideally stem cells should be autologous cells that can be harvested without difficulty from the patient. However, the number and differentiation ability of bone marrow-derived mesenchymal stem cells (BM-MSCs) significantly decreases with age (8). Human umbilical cord blood (hUCB) is an alternative source of MSCs, with several studies showing that hUCB-derived MSCs (hUCB-MSCs) are similar to BM-MSCs regarding cell characteristics and multilineage differentiation potential (9,10). Additionally, we have previously shown that hUCB-MSCs have the migratory capacity and tropism for gliomas, and can be used as a therapeutic vehicle for glioma therapy (11,12). However, the mechanism underlying the glioma tropism of hUCB-MSCs is not well understood.

Directed cell migration is initiated in response to chemotactants that include, cytokines and growth factors. Therefore, it is essential to understand the various factors that regulate hUCB-MSC migration to gliomas. Tumors and the surrounding inflamed tissue are known to express interleukin (IL)-1α, IL-1β, transforming growth factor (TGF)β, IL-10, tumor necrosis factor (TNF)α, TNFβ, interferon-gamma (IFNγ), and monocyte chemoattractant protein-1 (MCP-1) (13,14), and stem cells express the corresponding receptors (15,16). Thus, factors and their receptors might play roles in
the specific migration of MSCs towards infarcts and brain tumors. In our previous study, we demonstrated that hUCB-MSCs have a strong migration capacity toward glioma secreted IL-8 (11). Other factors expressed by tumors, including stromal cell-derived factor-1α (SDF-1α), vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), epidermal growth factor (EGF), and transmembrane protein 18 (TMEM18) have also been shown to be involved in migration of MSCs migration (17-22).

SDF-1α is a member of the CXC chemokine family, and its receptor CXCR4 was originally described as a regulator of cell interactions in the immune system. SDF-1α/CXCR4 in the central nervous system (CNS) suggests an important function in the migration of stem cells during CNS development. Recently, an essential role of SDF-1α/CXCR4 in tumor metastasis and vascularization was reported (23). Moreover, SDF-1α/CXCR4 plays an important and unique role in the regulation of stem cell trafficking. Its chemokine regulates the migration of hematopoietic stem cells (HSCs), their homing/migration in major bone marrow, and accumulation of immune cells in inflammatory tissue. Additionally, proper functioning of the SDF-1α/CXCR4 axis is important in engraftment, proliferation, and survival of HSCs (24). Therefore, we hypothesize that SDF-1/CXCR4 signaling plays an important role in tumor tropism of hUCB-MSCs and examined whether overexpression of CXCR4 on hUCB-MSCs enhances MSCs migratory capacity toward gliomas.

Materials and methods

Preparation of hUCB-MSC. Human UCB samples were obtained with consent of the mothers. The hUCB-MSCs were separated and maintained as previously described (9). hUCB-MSCs were cultured in α-MEM (Invitrogen) media containing 10% fetal bovine serum (FBS).

Cancer cell line and primary cell culture. U-87MG and U-251MG cells were obtained from the American Type Culture Collection and were maintained in Eagle’s MEM (EMEM; Hyclone) and DMEM (Hyclone), respectively. Normal human astrocytes were obtained from the Applied Cell Biology Research Institute and were cultured in DMEM. After ethical approval and written informed consent, fresh specimens of human brain tumors were harvested from patients undergoing surgery. Briefly, tissues were washed, finely minced, and then separated into brain tissue fractions using differential centrifugation. Each cell population was then cultured in DMEM. All media were supplemented with 2 μmol/l L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% FBS purchased from Hyclone. Cells were incubated at 35˚C in a humidified atmosphere containing 5% CO2.

Reverse transcription PCR. Total RNA was prepared from glioma cell lines and primary glioma cells using TRIzol (Invitrogen) according to the manufacturer’s instructions. cDNA was synthesized using 3 μg total RNA and oligo(dT) primer and Superscript II polymerase for reverse transcription PCR (Invitrogen). PCR amplifications consisted of a total of 35 cycles of denaturation at 94˚C for 30 sec, annealing at 52˚C for 30 sec, extension at 72˚C for 1 min with a first denaturation at 94˚C for 10 min, and final extension at 72˚C for 10 min. Target primers sequences used were as follows: SDF-1α forward: 5’-ATGAAACGGGATGTCGTCGA-3’, SDF-1α reverse: 5’-ACCTTTGTGTTAAGCTTTTCC-3’ and GAPDH forward: 5’-CCATTGACACTTGGGTAC-3’, GAPDH reverse: 5’-TGTACGCAAAAATTGGTCA-3’.

Transfection of hUCB-MSCs with CXCR4. Transfections of the hUCB-MSCs were conducted using the pcDNA-CXCR4 plasmid and the control of the moc-vector. Cells were resuspended in Resuspension buffer® (Invitrogen) at a density of 1x10⁶ cells/ml and incubated with 2 μg of plasmid. The Neon transfection system (Invitrogen) was performed at room temperature using program 3 (1600 voltage, 20 ms, one pulse). After transfection, cells were distributed into 35-mm-diameter cell culture dishes and placed at 37˚C in a 5% CO₂-humidified atmosphere.

For detection of transfected cells was used flow cytometry analysis. hUCB-MSCs were analyzed for the surface expression of SDF-1 receptor with anti-human CXCR4. Briefly, 2x10⁵ cells were incubated with anti-CD184 primary antibody (rat polyclonal anti-human CXCR4) for 20 min at 4˚C, and then washed three times with PBS. Following the final wash, the cells were resuspended in PBS and incubated with Alexa fluor 488 goat anti-rat secondary antibody (Invitrogen) for 20 min at 4˚C. After washing with PBS, the expressions of these receptors were analyzed by flow cytometry using the FACS Vantage SE system (Becton-Dickinson).

In vitro migration assay. Migration of human hUCB-MSCs was determined using Transwell plates (Corning Costar) that were 6.5 mm in diameter with 8-μm pore size filters. hUCB-MSCs (3x10⁴ cells) were added to the upper chamber, and 600 μl of conditioned medium or SDF-1α was added to the bottom chamber. For the experiment of migration of CXCR4 overexpressed hUCB-MSCs, conditioned medium with 1/3 diluted were used. After incubation for 5 h at 37˚C in an atmosphere of 5% CO₂, cells that had not migrated from the upper side of the filters were removed with a cotton swab and the lower side was stained using a Diff-Quik™ three-step stain set (Sysmex), mounted on glass slides. At least five random fields of view on each membrane were selected, and cells were counted using light microscopy with an Axiovert 200 microscope (Carl Zeiss) at magnification x200. Each experiment was performed in duplicate, with results expressed as mean ± standard deviation (SD).

In vivo migration assay. Human U-251MG glioma cells (5x10⁴ cells in 3 μl PBS) were injected into the right striatum of the nude mouse brain (AP + 1.0 mm, ML + 2.0 mm, and DV - 3.0 mm from bregma and dura) using a 10 AL Hamilton syringe connected with a 30-gauge needle at a speed of 0.5 μl/min. Then, 10⁵ cells of red fluorescent PKH26 dye (Sigma-Aldrich)-labeled CXCR4-overexpressing hMSCs were mixed with an equal number of green fluorescent PKH67 dye (Sigma-Aldrich)-labeled vector-control hMSCs and injected into the contralateral side of the mouse brain. The brain samples were collected 10 days later for cryosectioning (16-μm-thick sections) and counter staining. Migrating cells were detected...
using an AX70 fluorescence microscope (Olympus) or an LSM 510 Meta confocal microscope (Carl Zeiss).

**Statistical analysis.** Data from migration assays were compared by Student's t-test for two samples with unequal variances. Statistical significance was determined at the >0.05 level.

**Results**

**Migration of hUCB-MSCs toward gliomas.** Stem cells exhibit extensive tropism for experimental gliomas (25). To test this in hUCB-MSCs, *in vitro* migration assays using Transwell plates were conducted. hUCB-MSCs were cultured in the upper chamber and the target glioma cell (U-87MG, U-251MG, or primary cells)-conditioned medium was placed in the lower chamber. Conditioned medium from normal human astrocytes was used as the negative control. Only a few cells migrated toward serum-free medium and conditioned medium from normal human astrocytes, whereas the migration of hUCB-MSCs was significantly stimulated by human glioma cell lines or human glioma primary cells-conditioned medium (Fig. 1). These results were consistent with the capability of human glioma cells of stimulating the migration of hUCB-MSCs.

**Glioma-secreted SDF-1α induces CXCR4-dependent migration of hUCB-MSCs.** Factor released from glioma cells may be a potential chemotactrant involved in the tropism of stem cells (25). Among the various factors, SDF-1α has a potential role in stem cell tropism toward glioma. For example, SDF-1α from gliomas regulates the migration of neural stem cells (26). We confirmed expression of SDF-1α by RT-PCR in glioma cells. As the result, SDF-1α was expressed in all glioma cell lines and glioma primary cells (Fig. 2A). To examine the involvement of SDF-1α in the migration of hUCB-MSCs, hUCB-MSCs were treated with recombinant SDF-1α. The...
migration of hUCB-MSCs was significantly stimulated by SDF-1α in a dose-dependent manner (Fig. 2B), consistent with the suggestion. The SDF-1α affects the migration of hUCB-MSCs.

To more precisely define the involvement of SDF-1α in MSCs migration, glioma cell SDF-1α was neutralized by incubation in the presence of an antibody to SDF-1α in conditioned medium from glioma cells. Many cells migrated toward the glioma cell-conditioned medium incubated with an isotype-matched nonspecific antibody, but migration of hUCB-MSCs decreased significantly in the anti-SDF-1α-treated glioma cell-conditioned medium compared to untreated hUCB-MSCs. Bars, mean; error bars, standard error; p<0.05.

Figure 3. Glioma-secreted SDF-1α induces hUCB-MSCs migration. (A) Migration of MSCs when challenged with glioma conditioned medium before and after addition of SDF-1α antibody. (B) Addition of the CXCR4 antagonist AMD3100 significantly decreased hUCB-MSCs migration toward glioma-conditioned medium compared to untreated hUCB-MSCs. Bars, mean; error bars, standard error; p<0.05.

Overexpression of CXCR4 enhances the glioma-specific migration ability of UCB-MSCs. Previous results showed that SDF-1α induced hUCB-MSCs migration for glioma cells via its receptor CXCR4 (27). Presently, the endogenous expression of CXCR4 in hUCB-MSCs was examined using fluorescence-activated cell sorting (FACS). The percentage of CXCR4 positive cells was only 13%. To enhance hUCB-MSCs tropism for glioma cells, cells were transfected with a CXCR4 expression plasmid using a neon transfection system, by electrical gene transfer. The percentage of CXCR4-positive cell was 80% after transfection (Fig. 4A).

The next experiment investigated the migration activity of CXCR4-overexpressed hUCB-MSCs (hMSCs-CXCR4) toward glioma-conditioned medium and SDF-1α. hMSCs-CXCR4 displayed significantly higher migration capacity compared to untreated hUCB-MSCs (Fig. 4B). Bar graphs show the number of migrated hMSCs in the presence of glioma conditioned medium and SDF-1α, with and without the CXCR4 antagonist AMD3100. Bars, mean; error bars, standard error; p<0.05.
when compared with the control hUCB-MSCs. But, migration of hMSCs-CXCR4 and the control hMSCs to serum-free medium remained similar (Fig. 4B).

To assess the in vivo migration capacity of hMSC-CXCR4, PKH-26-labeled hMSCs-CXCR4 were injected together with PKH-67-labeled control hUCB-MSCs into the contralateral hemisphere of tumors in a U-251MG glioma model. PKH-26-labeled cells migrated more extensively from the initial injection site toward the tumor mass along the corpus callosum 10 days after injection of the cells (Fig. 5B and a-c). These observations were consistent with the view that hMSCs-CXCR4 possess excellent migratory capacity and glioma tropism in vitro.

Discussion

Despite advances in surgical and adjuvant therapy, the prognosis for malignant gliomas remains dismal. Viral vector-mediated therapeutic gene delivery involving direct injection into the primary brain tumor or postoperative tumor cavity often fails to reach outgrowing tumor islands because of the migratory abilities of the tumor cells and their marked infiltration into normal brain (28). Therefore, current treatments that rely on targeting the tumor mass are often ineffective.

Recently, the use of MSCs as vehicles for delivering therapeutic genes of glioma treatment was described (25). Cell-based gene therapy for gliomas depends crucially on tumor tropism. Previously, we reported that hUCB-MSCs can migrate toward human glioma cell lines (11,12). In addition, it was presently observed that hUCB-MSCs seem to have a migratory capacity toward conditioned medium from primary glioma cells (Fig. 1). However, to date, only a very small proportion of surviving grafted cells have been shown to be capable of integrating into the inflammatory sites (29). In addition, with increased understanding of the mechanistic underpinnings of MSC migration, the potential for enhancing...
MSC-targeted therapies appears promising (30). Therefore, our ultimate goal is to increase the specificity of hUCB-MSCs migration to gliomas.

In recent studies, soluble factors secreted from tumors were suggested as a critical factor for stem cell attraction. Glioma and the surrounding inflamed tissue express migratory factors, MCP-1, IL-8, uPA, EGF, and VEGF (20,31-34). Among the various factors, we focused on SDF-1α and its receptor CXCR4, which is known to mediate bone marrow-derived cell trafficking under normal and pathologic conditions (35). It has been reported that high-grade gliomas secrete significant levels of SDF-1α, and that the expression of this receptor CXCR4 correlates with the histological grade and invasive capacity of gliomas, as well as with tumor cell survival (36).

Ehtesham et al showed that SDF-1α/CXCR4 is important for glioma tropism of fetal neural progenitor/stem cells (26). The present data demonstrate that the functionality of the CXCR4, as judged by the chemotactic response of hUCB-MSCs to an SDF-1α gradient (Fig. 2). Presence of anti-SDF-1α or the CXCR4 antagonist AMD 3100 significantly inhibited chemotaxis of hUCB-MSCs toward glioma cell-conditioned medium, supporting a key role of SDF-1α/CXCR4 in hUCB-MSCs including gliomas (Fig. 3).

Non-viral methods of transfection are receiving increasing attention, given the several potential advantages over recombinant viruses. The present study used electrical mediation (the Neon transfection system) to transfect CXCR4 into hUCB-MSCs to examined the effect of CXCR4 on MSCs migration toward gliomas. The Neon transfection system is a new electroporation technology that uses a pipette tip as an electroporation space and a gold-coated electrode surface. Wang et al reported it to be safe and efficient in the transduction of human adipo-derived stem cells (hADSCs) (37), and presently allowed the successful overexpression of CXCR4 in hUCB-MSCs. Strong hMSCs-CXCR4 migration toward glioma cells was evident as compared with hUCB-MSCs (Fig. 4).

In vivo assessment of PKH26-labeled cells demonstrated that hMSCs-CXCR4 strongly migrate toward distant intracranial tumors, in contrast to the weak migration of hUCB-MSCs (Fig. 5). These observations are consistent with the view that hMSCs-CXCR4 that infiltrate a tumor may be a powerful vehicle to deliver suicide genes, proapoptotic genes, or immune modulators to the tumor. Recently, Sato et al demonstrated that EGFR modified bone marrow stromal cells and also transfected of INF-α to EGFR-MSCs strengthens this therapy approaches for refractory brain tumors (21).

In conclusion, the present data indicate that SDF-1/CXCR4 signaling is important for governing the process of hUCB-MSCs migration toward glioma cells. CXCR4 overexpression enhances migration of MSCs toward gliomas. Therefore, it is likely that hMSCs-CXCR4 will have their greatest applicability as a vehicle for delivering therapeutic genes for the tumor treatment.

Acknowledgments

This study was supported by a grant form the National R&D Program for Cancer Control (0820040) and the Korea Healthcare Technology R&D Project (A092258), Ministry of Health, Welfare and Family Affairs, Republic of Korea.

References

1. Davis FG, McCarthy BJ and Berger MS: Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. J Neurooncol 1: 205-211, 1999.


